Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer
The first results from the ProBio study show that treatment with ARPI leads to longer PFS, but Henrik Grönberg predicts that there will be many larger publications and results from the study in the future.